335 related articles for article (PubMed ID: 31273354)
41. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.
Salvatore B; Klain M; Nicolai E; D'Amico D; De Matteis G; Raddi M; Fonti R; Pellegrino T; Storto G; Cuocolo A; Pace L
Medicine (Baltimore); 2017 Oct; 96(42):e8344. PubMed ID: 29049252
[TBL] [Abstract][Full Text] [Related]
42. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
44. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
46. FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels.
Lebbink CA; de Vries LH; Borel Rinkes IHM; Braat AJAT; van Leeuwaarde RS; Lodewijk L; van Treijen MJC; Vriens MR; Valk GD; van Santen HM; de Keizer B
Eur J Endocrinol; 2022 May; 187(1):101-110. PubMed ID: 35521710
[TBL] [Abstract][Full Text] [Related]
47. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
48. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
49. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
[TBL] [Abstract][Full Text] [Related]
50. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
51. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
52. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
[TBL] [Abstract][Full Text] [Related]
53. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels.
Özdemir E; Yildirim Poyraz N; Polat SB; Turkolmez S; Ersoy R; Cakir B
Ann Nucl Med; 2014 Apr; 28(3):241-7. PubMed ID: 24379008
[TBL] [Abstract][Full Text] [Related]
55. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
56. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
Küçük ON; Gültekin SS; Aras G; Ibiş E
Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
[TBL] [Abstract][Full Text] [Related]
57. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
58. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
59. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody.
Liu Y
Nucl Med Commun; 2016 Jun; 37(6):577-82. PubMed ID: 26813991
[TBL] [Abstract][Full Text] [Related]
60. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]